- Home
- EVOK vs SNOA Comparison
EVOK vs SNOA Comparison
Compare EVOK & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVOK
- SNOA
- Stock Information
- Founded
- EVOK 2007
- SNOA 1999
- Country
- EVOK United States
- SNOA United States
- Employees
- EVOK N/A
- SNOA N/A
- Industry
- EVOK Biotechnology: Pharmaceutical Preparations
- SNOA Biotechnology: Pharmaceutical Preparations
- Sector
- EVOK Health Care
- SNOA Health Care
- Exchange
- EVOK Nasdaq
- SNOA Nasdaq
- Market Cap
- EVOK 4.3M
- SNOA 4.6M
- IPO Year
- EVOK 2013
- SNOA 2007
- Fundamental
- Price
- EVOK $4.45
- SNOA $3.05
- Analyst Decision
- EVOK
- SNOA
- Analyst Count
- EVOK 0
- SNOA 0
- Target Price
- EVOK N/A
- SNOA N/A
- AVG Volume (30 Days)
- EVOK 1.2M
- SNOA 574.4K
- Earning Date
- EVOK 11-07-2024
- SNOA 11-07-2024
- Dividend Yield
- EVOK N/A
- SNOA N/A
- EPS Growth
- EVOK N/A
- SNOA N/A
- EPS
- EVOK N/A
- SNOA N/A
- Revenue
- EVOK $8,617,036.00
- SNOA $13,547,000.00
- Revenue This Year
- EVOK $124.10
- SNOA $36.00
- Revenue Next Year
- EVOK $75.70
- SNOA $25.26
- P/E Ratio
- EVOK N/A
- SNOA N/A
- Revenue Growth
- EVOK 100.35
- SNOA 11.81
- 52 Week Low
- EVOK $3.54
- SNOA $2.52
- 52 Week High
- EVOK $17.40
- SNOA $9.40
- Technical
- Relative Strength Index (RSI)
- EVOK 40.54
- SNOA 49.12
- Support Level
- EVOK $4.28
- SNOA $2.70
- Resistance Level
- EVOK $4.79
- SNOA $3.60
- Average True Range (ATR)
- EVOK 0.45
- SNOA 0.29
- MACD
- EVOK -0.13
- SNOA 0.03
- Stochastic Oscillator
- EVOK 22.82
- SNOA 28.57
About EVOK Evoke Pharma Inc.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
About SNOA Sonoma Pharmaceuticals Inc.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.